Health Care·Pharmaceuticals·$547.6B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $1.63 | N/A | +13.27% |
management commentary, guidance changes, and full analysis available with Pro.
| +13.27% |
Tone: Cautiously Optimistic
Management expressed satisfaction with the earnings performance, particularly the EPS beat. They emphasized their commitment to long-term growth.
We are pleased with our performance this quarter.
Our focus remains on delivering value to our shareholders.
This earnings report shows that Johnson & Johnson managed to exceed expectations on EPS, which is a positive sign for the company's profitability. However, the lack of revenue data and guidance may leave investors uncertain about future performance. The stock reaction is currently not available, indicating that investors are still digesting the results.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
CSX CORP
Oct 13, 2015